Shi-Jian Wang

Shi-Jian Wang

Auto-generated profile, based on publicly available information

Shi-Jian Wang

Municipal Hospital Affiliated to Taizhou University, Taizhou 318000, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
JWjiabing wang
jiabing wang
DSDongsheng Sun
Dongsheng Sun
LHLili Huang
Lili Huang
SWShijian Wang
Shijian Wang
YJYong Jin
Yong Jin
Accumulating evidence shows that elevated levels of reactive oxygen species (ROS) are associated with cancer initiation, growth, and response to therapies. As concentrations increase, ROS influence cancer development in a paradoxical way, either triggering tumorigenesis and supporting the proliferation of cancer cells at moderate levels of ROS or causing cancer cell death at high levels of ROS. Thus, ROS can be considered an attractive target for therapy of cancer and two apparently contradictory but virtually complementary therapeutic strategies for the regulation of ROS to treat cancer. Despite tremendous resources being invested in prevention and treatment for cancer, cancer remains a leading cause of human deaths and brings a heavy burden to humans worldwide. Chemotherapy remains the key treatment for cancer therapy, but it produces harmful side effects. Meanwhile, the process of de novo development of new anticancer drugs generally needs increasing cost, long development cycle, and high risk of failure. The use of ROS‐based repurposed drugs may be one of the promising ways to overcome current cancer treatment challenges. In this review, we briefly introduce the source and regulation of ROS and then focus on the status of repurposed drugs based on ROS regulation for cancer therapy and propose the challenges and direction of ROS‐mediated cancer treatment.

28 December 2017 in World Chinese Journal of Digestology
Verified
Journal Article
Open access
XZXue-Feng Zhou
Xue-Feng Zhou
YHYing He
Ying He
SWShi-Jian Wang
Shi-Jian Wang
JWJin-Ming Wang
Jin-Ming Wang
WHWei-Yong Hong
Wei-Yong Hong
研究益生菌辅助应用对急性淋巴细胞白血病化疗后继发腹泻患者肠黏膜屏障功能及炎性细胞因子水平的影响. 选择2015-01/2016-12在台州市立医院治疗的化疗相关性腹泻患者90例. 随机分为对照组(n = 45)和观察组(n = 45), 对照组患者在常规对症支持治疗的基础上加用蒙脱石散, 观察组患者在对照组的基础上加用双歧杆菌三联活菌胶囊. 比较两组患者的临床疗效、肠黏膜屏障功能、炎性细胞因子水平及肠道菌群等. 观察组患者显效25例(55.56%), 有效17例(37.78%), 总有效率为93.33%, 对照组总有效率为75.56%(P<0.05). 治疗前两组患者的肠黏膜屏障功能指标水平相近(P>0.05), 治疗后两组患者的二胺氧化酶(diamine oxidase, DAO)、D-乳酸和内皮素(endothelin, ET)水平均明显下降, 观察组患者的DAO、D-乳酸和ET水平低于对照组(P<0.05). 治疗前两组患者的炎性细胞因子水平相近(P>0.05), 治疗后两组患者的肿瘤坏死因子-α(tumor necrosis factor alpha, TNF-α)、降钙素原(procalcitonin, PCT)和白介素(interleukin, IL)-6水平均明显下降, 观察组患者的TNF-α、PCT和IL-6水平低于对照组(P<0.05). 对照组治疗后的肠道菌群数值较治疗前明显降低, 观察组治疗后双歧杆菌、乳杆菌较治疗前明显增多, 观察组治疗后肠道菌群数值明显高于对照组(P<0.05), 观察组肠杆菌、肠球菌、大肠埃希菌数值治疗前后相近(P>0.05). 双歧杆菌辅助应用可以明显提高急性淋巴细胞白血病患者化疗相关性腹泻的临床疗效, 降低炎性细胞因子水平, 改善肠黏膜屏障功能, 调节肠道菌群平衡紊乱, 重建肠道生态平衡, 值得在临床推广.